Clinical Report: FDA Issues CRL for Orviglance NDA
Overview
The FDA has issued a Complete Response Letter for Ascelia Pharma's New Drug Application for Orviglance, indicating that the application cannot be approved in its current form. The FDA has requested additional clinical data and product documentation.
Background
Orviglance is an investigational oral MRI contrast agent aimed at improving the detection of focal liver lesions in patients with severe kidney impairment, where traditional gadolinium-based contrast agents may pose risks.
Data Highlights
No numerical data provided in the source material.
Key Findings
The FDA issued a Complete Response Letter for Orviglance's NDA, requesting additional data.
Ascelia Pharma plans to request a Type A meeting with the FDA for clarification.
Orviglance is designed for patients with severe kidney impairment requiring contrast-enhanced liver MRI.
The pivotal Phase 3 SPARKLE study met its primary endpoint, showing improved visualization of liver lesions.
The NDA was based on a development program that included nine clinical studies with positive efficacy and safety results.
Clinical Implications
Clinicians should remain informed about the status of this investigational agent.
Conclusion
The issuance of the Complete Response Letter reflects the regulatory process involved in the approval of new diagnostic agents.
